ArticleCurrent transplantation reports2020
CAR-Tregs as a Strategy for Inducing Graft Tolerance.
Article in Current transplantation reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- The Role of Chimeric Antigen Receptor Regulatory T Cells in Promoting Immune Tolerance in Solid Organ Transplantation:Saudi medical journal · 2026Review
- Review
- Perspectives on PCR-Based Cellular Kinetics and Biodistribution Analysis for Emerging Adoptive Cell Therapies.The AAPS journal · 2026Review
- CAR-engineered cell therapies: current understandings and future perspectives.Molecular biomedicine · 2026Review
- Regulatory T cell therapy in solid organ transplantation: mechanisms, translational progress, and remaining barriers.Frontiers in immunology · 2026Review
- Tolerogenic Therapies in Cardiac Transplantation.International journal of molecular sciences · 2025Review
- Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions.Frontiers in immunology · 2024Review
- Donor-Specific Blood Transfusion in Lung Transplantation.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Engineering human stem cell-derived islets to evade immune rejection and promote localized immune tolerance.Cell reports. Medicine · 2023Article
- Treg Therapy for the Induction of Immune Tolerance in Transplantation-Not Lost in Translation?International journal of molecular sciences · 2023Review
- Anti-HLA-A2-CAR Tregs prolong vascularized mouse heterotopic heart allograft survival.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2022Article
- Study Design: Human Leukocyte Antigen Class I Molecule AKidney international reports · 2022Article
- Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.Frontiers in immunology · 2021Article
- The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.Frontiers in immunology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
purpose of the reviewThe adoptive transfer of alloantigen-specific regulatory T cells (Tregs) following organ transplantation is an emerging treatment paradigm that may induce tolerance and reduce the risk for graft rejection. In particular, redirecting Treg specificity via expression of synthetic chimeric antigen receptors (CARs) has demonstrated therapeutic promise in several preclinical studies. In this review, we highlight recent progress and remaining barriers to the clinical translation of CAR-Treg therapies. RECENT
findingsCAR Tregs targeting human leukocyte antigen (HLA)-A2 showed antigen-specific SUMMARY: Donor HLA molecules are attractive candidate antigens to target with CAR Tregs in transplantation due to mismatched HLA only expressed on the transplanted organ. The feasibility of this approach has been demonstrated by several independent groups in recent years. However, substantial challenges in CAR design and preclinical modeling must be more extensively addressed prior to clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.